Browse diseases

…acteria in the human gut. D. welbionis abundance was reduced in MASLD across two cohorts and inversely correlated with fibrosis score…

…ions IL-23i therapy was associated with lower risks of incident liver disease and related outcomes in psoriasis, suggesting biologic selectio…

…n early marker of disease progression. IH was notably higher in MASH than in MASL, resulting in higher IH/DR ratios.Conclusion Speci…

…LREs (110 (2.5%) with hepatic decompensation and 59 (1.3%) with hepatocellular carcinoma). The two-step approach classified 72.6%, 6.8% and 20.6% of pat…

…3 4 Given the critical importance of non-invasive assessment of liver fibrosis for the clinical management of CHB,5 we evaluated the predictiv…

…patitis (MASH), which is linked to cirrhosis, liver failure and hepatocellular carcinoma. The recent approval of resmetirom and semaglutide1 2 for activ…

… observational study on the beneficial effects of statin use in steatotic liver disease.1 Using a large, multicentre database, the author reported that…

… Murray O, Grady J, Williams B, Pulvino J, Raimer BG. End-stage liver disease in a state prison population. Ann Epidemiol. 2007 Oct;17(10):80…

…6%), viral (6%) and other (8%). Indications for assessment were decompensated cirrhosis (82%), HCC (5%), variant syndromes (13%). Of the patients seen …

…ent, a Fibroscan, and completion liver screen. Interrogation of metabolic syndrome risk factors and alcohol screening takes place, with appropriat…

…ssociated steatotic liver disease (MASLD) is a leading cause of chronic liver disease (CLD). The EASL Lancet commission prioritises earlier diagnosis of fi…

… often not done routinely at the time of diagnosis. The rate of HCC remains low.Summary Venesection for haemochromatosis is safe, a…